Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights

By Dr. Matthew Watson

-- Received $167 million in aggregate gross proceeds in April from initial public offering --– Advancing lead oncology program BMF-219, a small molecule irreversible menin inhibitor, toward IND filing in second half of 2021 --

Read the rest here:
Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights

Related Post


categoriaGlobal News Feed commentoComments Off on Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights | dataMay 28th, 2021

About...

This author published 3912 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research